Groundbreaking Patent Acquisition by Inspira Technologies
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) recently achieved a significant milestone with the Japan Patent Office granting them Patent No. 7777598. This important patent pertains to their revolutionary Convertible Dual Lumen Cannula device and its unique method of use, marking a crucial step in securing exclusive rights within a highly advanced medical market.
Importance of the Dual Lumen Cannula Innovation
The granting of this patent ensures that Inspira Technologies holds exclusive commercial rights to their unique cannula technology in Japan until 2041. This achievement follows the company’s successful acquisition of a corresponding U.S. patent in 2023, strategically broadening its protective coverage across key healthcare economies.
Innovative Design Enhancements
The unique mechanism embedded within Inspira’s technology allows this single-lumen cannula to convert into a dual-lumen cannula without the need for additional surgical interventions after insertion. This breakthrough design not only prioritizes patient safety by minimizing infection risks, but also aims to enhance procedural efficacy while reducing overall costs compared to traditional dual-lumen alternatives.
Future Implications for Healthcare Solutions
Dagi Ben-Noon, CEO of Inspira Technologies, expressed enthusiasm about the impact of their patent on the market. He stated, "The traditional dual lumen cannulas are often high in production costs, and our patented convertible solution provides a more budget-friendly option that could significantly improve patient safety and streamline procedures. Having secured patents in both the U.S. and Japan solidifies our commitment to advancing respiratory support technology and opens doors for future disposable product revenue streams."
About Inspira Technologies and Continued Innovations
Inspira Technologies is a forward-looking medical device company dedicated to developing advanced respiratory support solutions and real-time blood monitoring systems. Their flagship product, the INSPIRA™ ART100 system, is FDA-cleared for use in various medical procedures including cardiopulmonary bypass and ECMO (Extracorporeal Membrane Oxygenation). This pioneering device represents the forefront of technology that aims to allow patients to remain awake while receiving treatment.
Continuous Advancement in Medical Technologies
Inspira is also working on the HYLA™ platform, a proprietary blood sensor that permits continuous and non-invasive blood monitoring, which can enhance patient care and increase operational efficiency in medical environments. As the company expands its intellectual property portfolio and streamlines operations, they are increasingly establishing themselves as a notable player in the MedTech sector.
Company Contact Details
For more information about Inspira Technologies and their innovative solutions, individuals may reach out through the following:
Email: info@inspirao2.com
Phone: +972-9-9664485
Frequently Asked Questions
What is the significance of the patent granted to Inspira Technologies?
The patent provides Inspira exclusive rights to their Convertible Dual Lumen Cannula device in Japan until 2041, enhancing their market position.
How does the dual lumen cannula work?
This innovative device can convert from a single-lumen to a dual-lumen setup intravascularly, allowing for greater flexibility during medical procedures.
What are the benefits of Inspira's cannula over traditional options?
Inspira’s cannula reduces costs, minimizes infection risk, and improves procedural efficiency compared to conventional dual-lumen solutions.
What products does Inspira Technologies offer?
Inspira offers the INSPIRA™ ART100 and is developing the next-generation INSPIRA ART500, alongside the HYLA™ non-invasive blood monitoring platform.
How can I contact Inspira Technologies for more information?
You can reach out via email at info@inspirao2.com or call +972-9-9664485.
